AstraZeneca entered into a definitive agreement Monday to acquire CinCor Pharma Inc. for up to $1.8 billion.
CinCor (NASDAQ: CINC), based in Waltham, Massachusetts, is developing new treatments for hypertension and chronic kidney disease. The company’s stock was up 137% at $27.91 per share in early morning trading.
The deal, which still requires shareholder and regulatory approval, is expected to be completed during the first quarter of this year.
CinCor raised $193.6 million with its Nasdaq…
